USA flag logo/image

An Official Website of the United States Government

Identification of novel therapeutics for tuberculosis combining cheminformatics,

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2010 / STTR
Agency Tracking Number:
R41AI088893
Solicitation Year:
2010
Solicitation Topic Code:
NIAID
Solicitation Number:
PA09-081
Small Business Information
COLLABORATIVE DRUG DISCOVERY, INC.
1633 Bayshore Hwy, Suite 342 BURLINGAME, CA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Identification of novel therapeutics for tuberculosis combining cheminformatics,
Agency: HHS
Contract: 1R41AI088893-01
Award Amount: $149,382.00
 

Abstract:

DESCRIPTION (provided by applicant): This Small Business Technology Transfer Phase I project entitled Identification of novel therapeutics for tuberculosis combining cheminformatics, diverse databases and logic-based pathway analysis describes the development of software that will facilitate new drug discovery efforts for Mycobacterium tuberculosis (TB). The amount of research performed on TB compared with other known pharmaceutical targets (cancer, heart disease, diabetes etc.) is limited primarily to disparate academic groups and small groups in big drug companies. There is no repository of global knowledge on TB that could assist in drug development efforts. We propose to develop a prototype system to facilitate new drug discovery efforts for TB using novel logical inference techniques developed by scientists at SRI International, which would be linked with knowledge which has been assembled by the curation of diverse biological data types and computational prediction by Collaborative Drug Discovery (CDD). This tool will be used to aid the Identification of novel therapeutics for Tuberculosis by combining cheminformatics, diverse databases and logic-based pathway analysis. It will represent a synergistic computational tool for hypotheses testing, knowledge sharing, data archiving, data mining and drug discovery. We expect a combined product would have considerable impact on TB research enabling further experimental validation of hypotheses in phase II. As TB is one of the world's deadliest diseases the value of our proposal would be high. The societal impact would be the ability to mine the deposited data, search for new potential targets and lead molecules and bring the data and researchers to a single centralized location. PUBLIC HEALTH RELEVANCE:We propose to develop a prototype system to facilitate new drug discovery efforts for TB using novel logical inference techniques developed by scientists at SRI International, which would be linked with knowledge which has been assembled by the curation ofdiverse biological data types and computational prediction by Collaborative Drug Discovery (CDD). This tool will be used to aid the Identification of Novel Therapeutics for Tuberculosis by combining Cheminformatics, Diverse Databases and Logic-based Pathway Analysis. It will represent a synergistic computational tool for hypotheses testing, knowledge sharing, data archiving, data mining and drug discovery.

Principal Investigator:

Sean Ekins
269-930-0974
sekins@collaborativedrug.com

Business Contact:

Sean Ekins
215-687-1320
sekins@collaborativedrug.com
Small Business Information at Submission:

COLLABORATIVE DRUG DISCOVERY, INC.
1633 Bayshore Hwy, Suite 342 BURLINGAME, CA -

EIN/Tax ID: 142163157
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
Sri International
333 RAVENSWOOD AVE
MENLO PARK, CA 94025-3493
Contact: